Increlex Injection, Solution
Product Images NDC 15054-1040

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Increlex (NDC 15054-1040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ipsen Biopharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Increlex 01)

FDA Label Image

Figure 1 (Increlex 02)

FDA Label Image

Figure 2 (Increlex 03)

FDA Label Image

Figure 3 (Increlex 04)

FDA Label Image

Figure 4 (Increlex 05)

FDA Label Image

Figures 5 And 6 (Increlex 06)

FDA Label Image

Figure 7 (Increlex 07)

FDA Label Image

Figure 8 (Increlex 08)

FDA Label Image

Figure (Increlex 09)

FDA Label Image

Figure (Increlex 10)

FDA Label Image

Figure (Increlex 11)

FDA Label Image

Figure (Increlex 12)

FDA Label Image

Figure A (Increlex 13)

FDA Label Image

Figure B (Increlex 14)

FDA Label Image

Principal Display Panel (40 mg Vial Carton)

This text contains information about a medication called "Increlex," which is a type of injection containing a combination of ingredients, including mecasermin and somatropin, used for subcutaneous use and should be kept refrigerated. The medication is available in multi-use vials and the unused material should be discarded after more than 30 days of the vials being opened. The product is distributed by Ispen Bopharmaceuticals, Inc. and the vials contain 40mg of medication each.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.